Last reviewed · How we verify
OPTIMOX-bevacizumab
OPTIMOX-bevacizumab combines oxaliplatin-based chemotherapy with bevacizumab, a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis.
OPTIMOX-bevacizumab combines oxaliplatin-based chemotherapy with bevacizumab, a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis. Used for Metastatic colorectal cancer (first-line treatment), Advanced colorectal cancer.
At a glance
| Generic name | OPTIMOX-bevacizumab |
|---|---|
| Also known as | Folinic acid (FA)-5-fluorouracil (5-FU)-oxaliplatin [OPTIMOX], Avastin |
| Sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
| Drug class | Monoclonal antibody (bevacizumab component) + chemotherapy regimen |
| Target | VEGF (vascular endothelial growth factor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
OPTIMOX is an intermittent oxaliplatin-fluorouracil chemotherapy regimen designed to reduce cumulative neurotoxicity while maintaining efficacy. Bevacizumab, a humanized anti-VEGF monoclonal antibody, prevents new blood vessel formation that tumors require for growth and metastasis. The combination leverages chemotherapy cytotoxicity with anti-angiogenic activity to improve outcomes in colorectal cancer.
Approved indications
- Metastatic colorectal cancer (first-line treatment)
- Advanced colorectal cancer
Common side effects
- Peripheral neuropathy
- Hypertension
- Proteinuria
- Bleeding
- Thromboembolism
- Gastrointestinal perforation
- Neutropenia
- Diarrhea
Key clinical trials
- QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. (PHASE3)
- Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (PHASE3)
- Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM) (PHASE3)
- Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OPTIMOX-bevacizumab CI brief — competitive landscape report
- OPTIMOX-bevacizumab updates RSS · CI watch RSS
- GERCOR - Multidisciplinary Oncology Cooperative Group portfolio CI